Full Press Release Details
BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of May.
Details are as follows:
H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQDate:Tuesday, May 19, 2026Time:1:30 PM ETWebcast Link:https://journey.ct.events/view/bc55d2f9-d121-4f7d-8129-1f69f201bd7f
2026 Stifel Virtual Targeted Oncology ForumDate:Wednesday, May 20, 2026Time:11:30 AM ETWebcast Link:https://event.summitcast.com/view/SScpdhHfwE8g9WsS8WcTax/QuhrzDf8Wdgui7i3FhuDb6
Virtual/Replay availability:Presentations will be archived on Compass’Eventspage.
Compass’ management will be available for one-on-one meetings during all events. Interested investors should contact their respective representatives to request meetings.
About Compass TherapeuticsCompass Therapeutics, Inc. was founded in 2014 and is headquartered in Boston, MA. Compass is a clinical-stage, oncology-focused biopharmaceutical company discovering and developing proprietary antibody-based therapeutics to treat multiple diseases. The company’s scientific focus is on the relationship between angiogenesis, the immune system and tumor growth. Compass has a robust pipeline of novel product candidates designed to target multiple key biological pathways to drive an effective anti-tumor response, including angiogenesis modulation, immune activation within the tumor microenvironment, and reduction of tumor-driven immunosuppression. The company is advancing discovery candidates through clinical development to commercial-stage assets. For more information, visitwww.compasstherapeutics.com.